Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):1–4

Article  Google Scholar 

Yeh WZ, Blizzard L, Taylor BV (2018) What is the actual prevalence of migraine? Brain Behav 8(6):e00950

Article  PubMed  PubMed Central  Google Scholar 

Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe H eadache: Results of the A merican Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1278–99.

Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631–649

Article  PubMed  Google Scholar 

Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P (2020) The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther 9:535–549

Article  PubMed  PubMed Central  Google Scholar 

Lattanzi S, Trinka E, Altamura C, Del Giovane C, Silvestrini M, Brigo F et al (2022) Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety. Neurol Ther 11(3):1235–1252

Article  PubMed  PubMed Central  Google Scholar 

Khalil M, Moreno-Ajona D, Villar-Martínez MD, Greenwood F, Hoffmann J, Goadsby PJ (2022) Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol 29(8):2473–2480

Article  PubMed  PubMed Central  Google Scholar 

Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30(5):599–609

Article  CAS  PubMed  Google Scholar 

Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M et al (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 23(1):122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berg J (2004) Economic Evidence in Migraine and Other Headaches: A Review. Eur J Health Econ 5:S43-54

Article  PubMed  Google Scholar 

Lanteri-Minet M (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18(1):1–6

Article  Google Scholar 

Lantéri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31(7):837–850

Article  PubMed  Google Scholar 

Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B et al (2020) Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ 23(1):113–123

Article  PubMed  Google Scholar 

Diener H-C, Charles A, Goadsby PJ, Holle D (2015) New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 14(10):1010–1022

Article  CAS  PubMed  Google Scholar 

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008

Article  CAS  PubMed  Google Scholar 

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132

Article  CAS  PubMed  Google Scholar 

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122

Article  CAS  PubMed  Google Scholar 

Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW et al (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16(7):877–887

Article  PubMed  Google Scholar 

Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P (2019) Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clin Drug Investig 39(10):979–990

Article  PubMed  Google Scholar 

Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgstrom F (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 21(1):99

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A et al (2021) Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden. Pharmacoeconomics 39(3):357–372

Article  PubMed  Google Scholar 

Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia 38(10):1644–1657

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value in health 25(1):10–31

Article  PubMed  Google Scholar 

Naghdi S, Underwood M, Madan J, Brown A, Duncan C, Matharu M, et al. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. Manuscript submitted for publication.

Royle P, Cummins E, Walker C, Chong S, Kandala N-B, Waugh N. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine - Single Technology Apprasial. Warwick Evidence; 2011.

Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–814

Article  CAS  PubMed  Google Scholar 

Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803

Article  CAS  PubMed  Google Scholar 

Mistry H, Naghdi S, Brown A, Rees S, Madan J, Grove A, et al. What is the comparative clinical and cost-effectiveness of pharmacological treatments for adults with chronic migraine? Health Technology Assessment. Manuscript submitted for publication.

Underwood M, Achana F, Carnes D, Eldridge S, Ellard DR, Griffiths F et al (2023) Supportive self-management program for people with chronic headaches and migraine: a randomized controlled trial and economic evaluation. Neurology 100(13):e1339–e1352

Article  PubMed  PubMed Central  Google Scholar 

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernández-Alava M, Pudney S (2018) EQ5Dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L. Stand Genomic Sci 18(2):395–415

Google Scholar 

National Institute for Health and Care Excellence. British National Formulary (BNF) 2022 [updated updated 14th December 2022. Available from: https://bnf.nice.org.uk/.

National Institute for Health and Care Excellence. Single Technology Appraisal: Fremanezumab for preventing migraine [ID1368] - Committee Papers. London. 2019.

National Institute for Health and Care Excellence. Single Technology Appraisal: Galcanezumab for preventing migraine [ID1372] - Committee Papers. London. 2020.

Jones KC, Burns A. Unit costs of health and social care. 2021.

NHS England. NHS Tariff 2018/2019 2020 [Available from: https://www.england.nhs.uk/publication/past-national-tariffs-documents-and-policies/.

NHS England. NHS Tariff 2021/2022 2022 [Available from: https://www.england.nhs.uk/publication/past-national-tariffs-documents-and-policies/.

Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31(3):301–315

Article  CAS  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Galcanezumab for preventing migraine. Technology appraisal guidance. 2020 18 November.

National Institute for Health and Care Excellence. Fremanezumab for preventing migraine. Technology appraisal guidance [TA764] 2022 [updated 02 February 2022. Available from: https://www.nice.org.uk/guidance/ta764.

Office for National Statistics. UK Interim Life Tables, 1980–1982 to 2018–2020. 2021.

Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in health 15(5):708–715

Article  PubMed  Google Scholar 

Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S et al (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ 21(7):666–675

Article  PubMed  Google Scholar 

Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371(9):796–797

Article  CAS  PubMed  Google Scholar